1) Weil YA, Rivkin G, Safran O, et al. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 2011;71(1):186-90.
2) Prasarn ML, Ahn J, Helfet DL, et al. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 2012;470(8):2295-301.
3) 藤原達司,松村宣政,西井 孝.非定型大腿骨骨折の診断のpitfall—他の運動器疾患と紛らわしい前駆症状について.日本骨粗鬆症会誌2019;5(4):47-51.
4) Saleh A, Hedge VV, Potty AG, et al. Management strategy for symptomatic bisphosphonate- associated incomplete atypical femoral fractures. HSS J 2012;8(2):103-10.
5) Koh JS, Goh SK, Png MA, et al. Femoral cortical stress lesions in long-term bisphosphonate therapy:①A herald of impending fracture? J Orthop Trauma 2010;24(2):75-81.
6) Lee YK, Ha YC, Kang BJ, et al. Predicting need for fixation of atypical femoral fracture. J Clin Endocrinol Metab 2013;98(7):2742-5.
7) Cho JW, Oh CW, Leung F, et al. Healing of atypical subtrochanteric femur. Fractures after cephalomedullary nailing:which factors predict union? J Orthop Trauma 2017;31(3):138-45.
8) Min BW, Koo KH, Park YS, et al. Scoring system for identifying impending complete fractures in incomplete atypical femoral Fractures. J Clin Endocrinol Metab 2017;102(2):545-50.
9) Giusti A, Hamdy NAT, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010;47(2):169-80.
10) Banffy MB, Vrahas MS, Ready JE, et al. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 2011;469(7):2028-34.
11) Das De S, Setiobudi T, Shen L, et al. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 2010;92(5):679-86.